CN101945990A - 基于分子印记聚合物的小分子和蛋白质分析装置 - Google Patents

基于分子印记聚合物的小分子和蛋白质分析装置 Download PDF

Info

Publication number: CN101945990A
Authority: CN; China
Prior art keywords: analyte; conjugates; reporter; wedding agent; sample
Prior art date: 2007-12-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN2008801268886A

Other languages

English (en)

Chinese (zh)

Inventor

拉斐尔·李维

伊多·马葛利特

雅登·德鲁米

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

INFIGO DIAGNOSTICS Ltd

Original Assignee

INFIGO DIAGNOSTICS Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-12-27

Filing date

2008-12-28

Publication date

2011-01-12

2008-12-28 Application filed by INFIGO DIAGNOSTICS Ltd filed Critical INFIGO DIAGNOSTICS Ltd

2011-01-12 Publication of CN101945990A publication Critical patent/CN101945990A/zh

Status Pending legal-status Critical Current

Links

102000004169 proteins and genes Human genes 0.000 title claims abstract description 33
108090000623 proteins and genes Proteins 0.000 title claims abstract description 33
150000003384 small molecules Chemical class 0.000 title claims abstract description 9
229920000344 molecularly imprinted polymer Polymers 0.000 title claims description 200
238000004458 analytical method Methods 0.000 title claims description 26
239000007788 liquid Substances 0.000 claims abstract description 195
238000000034 method Methods 0.000 claims abstract description 119
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 32
239000012530 fluid Substances 0.000 claims abstract description 10
208000015181 infectious disease Diseases 0.000 claims abstract description 9
239000012491 analyte Substances 0.000 claims description 571
239000000562 conjugate Substances 0.000 claims description 476
239000000523 sample Substances 0.000 claims description 369
230000027455 binding Effects 0.000 claims description 343
239000003795 chemical substances by application Substances 0.000 claims description 250
239000007787 solid Substances 0.000 claims description 125
239000011735 vitamin B7 Substances 0.000 claims description 76
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 64
229930003756 Vitamin B7 Natural products 0.000 claims description 52
235000011912 vitamin B7 Nutrition 0.000 claims description 52
102000000584 Calmodulin Human genes 0.000 claims description 49
108010041952 Calmodulin Proteins 0.000 claims description 49
230000009870 specific binding Effects 0.000 claims description 47
239000000126 substance Substances 0.000 claims description 43
238000012360 testing method Methods 0.000 claims description 41
108010087904 neutravidin Proteins 0.000 claims description 38
238000013459 approach Methods 0.000 claims description 26
239000000463 material Substances 0.000 claims description 24
239000003053 toxin Substances 0.000 claims description 22
108090000790 Enzymes Proteins 0.000 claims description 21
102000004190 Enzymes Human genes 0.000 claims description 21
-1 weedicide Substances 0.000 claims description 21
238000010521 absorption reaction Methods 0.000 claims description 19
231100000765 toxin Toxicity 0.000 claims description 19
108700012359 toxins Proteins 0.000 claims description 19
239000003153 chemical reaction reagent Substances 0.000 claims description 18
238000001035 drying Methods 0.000 claims description 17
239000010408 film Substances 0.000 claims description 17
238000001514 detection method Methods 0.000 claims description 16
239000002245 particle Substances 0.000 claims description 16
239000011148 porous material Substances 0.000 claims description 14
229920006395 saturated elastomer Polymers 0.000 claims description 14
239000000758 substrate Substances 0.000 claims description 14
150000002632 lipids Chemical class 0.000 claims description 13
229920002678 cellulose Polymers 0.000 claims description 12
239000001913 cellulose Substances 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 12
238000006116 polymerization reaction Methods 0.000 claims description 12
108090001008 Avidin Proteins 0.000 claims description 11
239000002250 absorbent Substances 0.000 claims description 11
230000002745 absorbent Effects 0.000 claims description 11
239000000427 antigen Substances 0.000 claims description 11
108091007433 antigens Proteins 0.000 claims description 11
102000036639 antigens Human genes 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 11
150000007523 nucleic acids Chemical class 0.000 claims description 11
108090001090 Lectins Proteins 0.000 claims description 10
102000004856 Lectins Human genes 0.000 claims description 10
239000005556 hormone Substances 0.000 claims description 10
229940088597 hormone Drugs 0.000 claims description 10
239000002523 lectin Substances 0.000 claims description 10
239000000178 monomer Substances 0.000 claims description 9
108020004707 nucleic acids Proteins 0.000 claims description 9
102000039446 nucleic acids Human genes 0.000 claims description 9
239000000700 radioactive tracer Substances 0.000 claims description 9
108060003951 Immunoglobulin Proteins 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 8
235000013305 food Nutrition 0.000 claims description 8
102000018358 immunoglobulin Human genes 0.000 claims description 8
239000013641 positive control Substances 0.000 claims description 8
239000000047 product Substances 0.000 claims description 8
101710153593 Albumin A Proteins 0.000 claims description 7
108010090804 Streptavidin Proteins 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 7
239000000090 biomarker Substances 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 7
239000000975 dye Substances 0.000 claims description 7
241000894006 Bacteria Species 0.000 claims description 6
206010008631 Cholera Diseases 0.000 claims description 6
231100000678 Mycotoxin Toxicity 0.000 claims description 6
101710120037 Toxin CcdB Proteins 0.000 claims description 6
150000001615 biotins Chemical class 0.000 claims description 6
230000000295 complement effect Effects 0.000 claims description 6
239000002636 mycotoxin Substances 0.000 claims description 6
238000002203 pretreatment Methods 0.000 claims description 6
239000003981 vehicle Substances 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 5
108010039491 Ricin Proteins 0.000 claims description 5
239000013543 active substance Substances 0.000 claims description 5
239000006227 byproduct Substances 0.000 claims description 5
201000011510 cancer Diseases 0.000 claims description 5
239000007850 fluorescent dye Substances 0.000 claims description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 4
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
239000012141 concentrate Substances 0.000 claims description 4
MZZBPDKVEFVLFF-UHFFFAOYSA-N cyanazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)(C)C#N)=N1 MZZBPDKVEFVLFF-UHFFFAOYSA-N 0.000 claims description 4
238000003745 diagnosis Methods 0.000 claims description 4
238000010828 elution Methods 0.000 claims description 4
230000007613 environmental effect Effects 0.000 claims description 4
230000002209 hydrophobic effect Effects 0.000 claims description 4
239000006249 magnetic particle Substances 0.000 claims description 4
239000002207 metabolite Substances 0.000 claims description 4
239000013528 metallic particle Substances 0.000 claims description 4
239000002096 quantum dot Substances 0.000 claims description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
238000000163 radioactive labelling Methods 0.000 claims description 4
239000004065 semiconductor Substances 0.000 claims description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
229930003231 vitamin Natural products 0.000 claims description 4
235000013343 vitamin Nutrition 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
229940088594 vitamin Drugs 0.000 claims description 4
150000003722 vitamin derivatives Chemical class 0.000 claims description 4
208000023275 Autoimmune disease Diseases 0.000 claims description 3
108030001720 Bontoxilysin Proteins 0.000 claims description 3
241000589876 Campylobacter Species 0.000 claims description 3
241000606069 Chlamydiaceae Species 0.000 claims description 3
241000193403 Clostridium Species 0.000 claims description 3
102000004127 Cytokines Human genes 0.000 claims description 3
108090000695 Cytokines Proteins 0.000 claims description 3
241000701022 Cytomegalovirus Species 0.000 claims description 3
241000725619 Dengue virus Species 0.000 claims description 3
206010013654 Drug abuse Diseases 0.000 claims description 3
241001115402 Ebolavirus Species 0.000 claims description 3
241000991587 Enterovirus C Species 0.000 claims description 3
101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 3
241000725303 Human immunodeficiency virus Species 0.000 claims description 3
206010020850 Hyperthyroidism Diseases 0.000 claims description 3
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 3
241000186359 Mycobacterium Species 0.000 claims description 3
201000005702 Pertussis Diseases 0.000 claims description 3
241000711798 Rabies lyssavirus Species 0.000 claims description 3
241000725643 Respiratory syncytial virus Species 0.000 claims description 3
241000702670 Rotavirus Species 0.000 claims description 3
241000315672 SARS coronavirus Species 0.000 claims description 3
241000607142 Salmonella Species 0.000 claims description 3
241000607768 Shigella Species 0.000 claims description 3
241000700584 Simplexvirus Species 0.000 claims description 3
102000013275 Somatomedins Human genes 0.000 claims description 3
241000191940 Staphylococcus Species 0.000 claims description 3
241000194017 Streptococcus Species 0.000 claims description 3
206010043376 Tetanus Diseases 0.000 claims description 3
108010055044 Tetanus Toxin Proteins 0.000 claims description 3
241000589886 Treponema Species 0.000 claims description 3
241000710886 West Nile virus Species 0.000 claims description 3
241000710772 Yellow fever virus Species 0.000 claims description 3
241000607734 Yersinia <bacteria> Species 0.000 claims description 3
230000009849 deactivation Effects 0.000 claims description 3
238000010790 dilution Methods 0.000 claims description 3
239000012895 dilution Substances 0.000 claims description 3
206010013023 diphtheria Diseases 0.000 claims description 3
238000004821 distillation Methods 0.000 claims description 3
231100000655 enterotoxin Toxicity 0.000 claims description 3
239000008187 granular material Substances 0.000 claims description 3
208000006454 hepatitis Diseases 0.000 claims description 3
231100000283 hepatitis Toxicity 0.000 claims description 3
208000003532 hypothyroidism Diseases 0.000 claims description 3
230000002989 hypothyroidism Effects 0.000 claims description 3
238000009776 industrial production Methods 0.000 claims description 3
239000012678 infectious agent Substances 0.000 claims description 3
230000002452 interceptive effect Effects 0.000 claims description 3
230000000968 intestinal effect Effects 0.000 claims description 3
239000002502 liposome Substances 0.000 claims description 3
208000011117 substance-related disease Diseases 0.000 claims description 3
229940118376 tetanus toxin Drugs 0.000 claims description 3
LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 claims description 3
229930013292 trichothecene Natural products 0.000 claims description 3
241000712461 unidentified influenza virus Species 0.000 claims description 3
229940051021 yellow-fever virus Drugs 0.000 claims description 3
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 2
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 2
WVQBLGZPHOPPFO-UHFFFAOYSA-N 2-chloro-N-(2-ethyl-6-methylphenyl)-N-(1-methoxypropan-2-yl)acetamide Chemical compound CCC1=CC=CC(C)=C1N(C(C)COC)C(=O)CCl WVQBLGZPHOPPFO-UHFFFAOYSA-N 0.000 claims description 2
WBLZUCOIBUDNBV-UHFFFAOYSA-N 3-nitropropanoic acid Chemical compound OC(=O)CC[N+]([O-])=O WBLZUCOIBUDNBV-UHFFFAOYSA-N 0.000 claims description 2
229930195730 Aflatoxin Natural products 0.000 claims description 2
XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 claims description 2
102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 2
108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 2
XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 2
WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims description 2
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
229930182566 Gentamicin Natural products 0.000 claims description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
241000712079 Measles morbillivirus Species 0.000 claims description 2
QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims description 2
229930003448 Vitamin K Natural products 0.000 claims description 2
239000005409 aflatoxin Substances 0.000 claims description 2
XCSGPAVHZFQHGE-UHFFFAOYSA-N alachlor Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl XCSGPAVHZFQHGE-UHFFFAOYSA-N 0.000 claims description 2
229940025084 amphetamine Drugs 0.000 claims description 2
229910052785 arsenic Inorganic materials 0.000 claims description 2
RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 2
MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 claims description 2
230000001580 bacterial effect Effects 0.000 claims description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
239000013068 control sample Substances 0.000 claims description 2
WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims description 2
229960000648 digitoxin Drugs 0.000 claims description 2
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
229960005156 digoxin Drugs 0.000 claims description 2
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
229940079593 drug Drugs 0.000 claims description 2
239000002359 drug metabolite Substances 0.000 claims description 2
239000003344 environmental pollutant Substances 0.000 claims description 2
229960005139 epinephrine Drugs 0.000 claims description 2
229960005309 estradiol Drugs 0.000 claims description 2
229930182833 estradiol Natural products 0.000 claims description 2
230000001076 estrogenic effect Effects 0.000 claims description 2
239000003337 fertilizer Substances 0.000 claims description 2
230000002538 fungal effect Effects 0.000 claims description 2
229960002518 gentamicin Drugs 0.000 claims description 2
230000006698 induction Effects 0.000 claims description 2
239000002917 insecticide Substances 0.000 claims description 2
229960004194 lidocaine Drugs 0.000 claims description 2
229910052744 lithium Inorganic materials 0.000 claims description 2
229960001078 lithium Drugs 0.000 claims description 2
229960000485 methotrexate Drugs 0.000 claims description 2
239000002858 neurotransmitter agent Substances 0.000 claims description 2
229960005489 paracetamol Drugs 0.000 claims description 2
229940049547 paraxin Drugs 0.000 claims description 2
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 2
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
239000000186 progesterone Substances 0.000 claims description 2
229960003387 progesterone Drugs 0.000 claims description 2
229960001404 quinidine Drugs 0.000 claims description 2
ODCWYMIRDDJXKW-UHFFFAOYSA-N simazine Chemical compound CCNC1=NC(Cl)=NC(NCC)=N1 ODCWYMIRDDJXKW-UHFFFAOYSA-N 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
229960003604 testosterone Drugs 0.000 claims description 2
229960000278 theophylline Drugs 0.000 claims description 2
230000009385 viral infection Effects 0.000 claims description 2
235000019168 vitamin K Nutrition 0.000 claims description 2
239000011712 vitamin K Substances 0.000 claims description 2
150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
229940046010 vitamin k Drugs 0.000 claims description 2
102000004196 processed proteins & peptides Human genes 0.000 abstract description 11
229920001184 polypeptide Polymers 0.000 abstract description 10
238000005259 measurement Methods 0.000 abstract description 5
208000035473 Communicable disease Diseases 0.000 abstract 1
235000018102 proteins Nutrition 0.000 description 26
239000010931 gold Substances 0.000 description 18
229910052737 gold Inorganic materials 0.000 description 18
238000002360 preparation method Methods 0.000 description 15
238000007598 dipping method Methods 0.000 description 14
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
238000010572 single replacement reaction Methods 0.000 description 11
239000008279 sol Substances 0.000 description 11
230000000007 visual effect Effects 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 10
238000012986 modification Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
239000000020 Nitrocellulose Substances 0.000 description 8
230000009471 action Effects 0.000 description 8
239000011248 coating agent Substances 0.000 description 8
238000000576 coating method Methods 0.000 description 8
230000008878 coupling Effects 0.000 description 8
238000010168 coupling process Methods 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 8
238000005516 engineering process Methods 0.000 description 8
238000003384 imaging method Methods 0.000 description 8
229920001220 nitrocellulos Polymers 0.000 description 8
210000002381 plasma Anatomy 0.000 description 8
230000008569 process Effects 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
238000003556 assay Methods 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000003287 optical effect Effects 0.000 description 6
238000012856 packing Methods 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
238000004445 quantitative analysis Methods 0.000 description 6
238000011160 research Methods 0.000 description 6
AUTOLBMXDDTRRT-JGVFFNPUSA-N (4R,5S)-dethiobiotin Chemical compound C[C@@H]1NC(=O)N[C@@H]1CCCCCC(O)=O AUTOLBMXDDTRRT-JGVFFNPUSA-N 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
239000000835 fiber Substances 0.000 description 5
238000013508 migration Methods 0.000 description 5
230000005012 migration Effects 0.000 description 5
238000012544 monitoring process Methods 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
238000000926 separation method Methods 0.000 description 5
DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 4
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 4
238000013016 damping Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Substances CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 4
239000000284 extract Substances 0.000 description 4
210000003677 hemocyte Anatomy 0.000 description 4
229940000351 hemocyte Drugs 0.000 description 4
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
230000000750 progressive effect Effects 0.000 description 4
125000006850 spacer group Chemical group 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920000936 Agarose Polymers 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
108091092195 Intron Proteins 0.000 description 3
239000011324 bead Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 3
238000011010 flushing procedure Methods 0.000 description 3
230000036571 hydration Effects 0.000 description 3
238000006703 hydration reaction Methods 0.000 description 3
238000003018 immunoassay Methods 0.000 description 3
230000037361 pathway Effects 0.000 description 3
229920002981 polyvinylidene fluoride Polymers 0.000 description 3
238000003380 quartz crystal microbalance Methods 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000000243 solution Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
208000036829 Device dislocation Diseases 0.000 description 2
238000009007 Diagnostic Kit Methods 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000723873 Tobacco mosaic virus Species 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
239000011358 absorbing material Substances 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
108010068678 beta Subunit Thyrotropin Proteins 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000012447 hatching Effects 0.000 description 2
229960000890 hydrocortisone Drugs 0.000 description 2
238000005470 impregnation Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000004816 latex Substances 0.000 description 2
229920000126 latex Polymers 0.000 description 2
YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000003821 menstrual periods Effects 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
238000000206 photolithography Methods 0.000 description 2
229920006254 polymer film Polymers 0.000 description 2
230000011664 signaling Effects 0.000 description 2
239000002689 soil Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000003068 static effect Effects 0.000 description 2
238000003860 storage Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229920001059 synthetic polymer Polymers 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
238000009736 wetting Methods 0.000 description 2
BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
WYGWHHGCAGTUCH-UHFFFAOYSA-N 2-[(2-cyano-4-methylpentan-2-yl)diazenyl]-2,4-dimethylpentanenitrile Chemical compound CC(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)C WYGWHHGCAGTUCH-UHFFFAOYSA-N 0.000 description 1
UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
BEYOBVMPDRKTNR-BUHFOSPRSA-N 4-Hydroxyazobenzene Chemical compound C1=CC(O)=CC=C1\N=N\C1=CC=CC=C1 BEYOBVMPDRKTNR-BUHFOSPRSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
239000012103 Alexa Fluor 488 Substances 0.000 description 1
108010083590 Apoproteins Proteins 0.000 description 1
102000006410 Apoproteins Human genes 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000283153 Cetacea Species 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
102400000011 Cytochrome b-c1 complex subunit 9 Human genes 0.000 description 1
101800000778 Cytochrome b-c1 complex subunit 9 Proteins 0.000 description 1
102100030497 Cytochrome c Human genes 0.000 description 1
108010075031 Cytochromes c Proteins 0.000 description 1
206010011953 Decreased activity Diseases 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
238000006424 Flood reaction Methods 0.000 description 1
238000012695 Interfacial polymerization Methods 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
QTUVCTXXMOZFHS-UHFFFAOYSA-N N-(8-aminooctyl)-2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetamide Chemical compound NCCCCCCCCNC(=O)COC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O QTUVCTXXMOZFHS-UHFFFAOYSA-N 0.000 description 1
206010029216 Nervousness Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
240000007591 Tilia tomentosa Species 0.000 description 1
206010048222 Xerosis Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000011616 biotin Chemical class 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
238000011088 calibration curve Methods 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
230000008859 change Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000002575 chemical warfare agent Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000007872 degassing Methods 0.000 description 1
238000000151 deposition Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000012631 diagnostic technique Methods 0.000 description 1
238000001903 differential pulse voltammetry Methods 0.000 description 1
230000005611 electricity Effects 0.000 description 1
230000005518 electrochemistry Effects 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
HDERJYVLTPVNRI-UHFFFAOYSA-N ethene;ethenyl acetate Chemical group C=C.CC(=O)OC=C HDERJYVLTPVNRI-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000004880 explosion Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000002657 fibrous material Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001917 fluorescence detection Methods 0.000 description 1
238000007421 fluorometric assay Methods 0.000 description 1
238000004374 forensic analysis Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
230000005484 gravity Effects 0.000 description 1
CKAPSXZOOQJIBF-UHFFFAOYSA-N hexachlorobenzene Chemical compound ClC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl CKAPSXZOOQJIBF-UHFFFAOYSA-N 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000002372 labelling Methods 0.000 description 1
238000002386 leaching Methods 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
238000011068 loading method Methods 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
ZIYVHBGGAOATLY-UHFFFAOYSA-N methylmalonic acid Chemical compound OC(=O)C(C)C(O)=O ZIYVHBGGAOATLY-UHFFFAOYSA-N 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004001 molecular interaction Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
239000000863 peptide conjugate Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000000419 plant extract Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000003361 porogen Substances 0.000 description 1
230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
238000010926 purge Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002910 solid waste Substances 0.000 description 1
238000004611 spectroscopical analysis Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000004365 square wave voltammetry Methods 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
238000010557 suspension polymerization reaction Methods 0.000 description 1
BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
238000012549 training Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000002699 waste material Substances 0.000 description 1

Images

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2600/00—Assays involving molecular imprinted polymers/polymers created around a molecular template

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

CN2008801268886A 2007-12-27 2008-12-28 基于分子印记聚合物的小分子和蛋白质分析装置 Pending CN101945990A (zh)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US1682907P	2007-12-27	2007-12-27
US61/016,829		2007-12-27
US2746208P	2008-02-10	2008-02-10
US61/027,462		2008-02-10
PCT/IL2008/001688 WO2009083975A2 (fr)	2007-12-27	2008-12-28	Dispositifs d'analyse de petites molécules et de protéines à partir de polymères à empreintes moléculaires

Publications (1)

Publication Number	Publication Date
CN101945990A true CN101945990A (zh)	2011-01-12

Family

ID=40824816

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN2008801268886A Pending CN101945990A (zh)	2007-12-27	2008-12-28	基于分子印记聚合物的小分子和蛋白质分析装置

Country Status (4)

Country	Link
EP (1)	EP2245135A4 (fr)
JP (1)	JP2011508233A (fr)
CN (1)	CN101945990A (fr)
WO (1)	WO2009083975A2 (fr)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102417558A (zh) *	2011-11-21	2012-04-18	嘉兴学院	一种分离莠去津的磁性分子印记聚合物及其制备方法
CN102507261A (zh) *	2011-10-20	2012-06-20	东北大学	一种选择性定量采集水环境中砷的方法
CN105004855A (zh) *	2014-04-16	2015-10-28	万冰	一种侧向流动检测测试条
CN106526176A (zh) *	2016-12-05	2017-03-22	无锡艾科瑞思产品设计与研究有限公司	一种多功能荧光免疫层析快速定量检测卡
CN106645109A (zh) *	2016-12-29	2017-05-10	Tcl集团股份有限公司	一种检测激素的方法、装置及系统
CN106872689A (zh) *	2017-01-10	2017-06-20	宁波大学	一种快速测定磺胺类抗生素残留的仿生酶联免疫检测方法
CN107478759A (zh) *	2016-06-08	2017-12-15	南京医科大学	基于分子印记纳米磁珠与质谱联用用于大鼠粪便中三七总皂苷代谢物质群的检测方法
CN111116823A (zh) *	2018-10-31	2020-05-08	华中科技大学	一种筛选甲状腺素干扰物材料的制备方法及应用
CN113731518A (zh) *	2016-03-18	2021-12-03	奎多心血管股份有限公司	微流体装置、系统及方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20130137117A1 (en) *	2009-07-23	2013-05-30	Raphael Levi	Method for preparing protein imprinted polymers and use thereof
CN102169120B (zh) *	2010-02-25	2014-09-17	艾博生物医药(杭州)有限公司	检测装置
CN101816927B (zh) *	2010-04-30	2012-11-14	南开大学	温敏型蛋白质分子印迹整体柱及其制备方法和应用
WO2012138429A1 (fr) *	2011-02-25	2012-10-11	University Of South Florida	Polymères à empreinte moléculaire ayant une affinité pour les peptides natriurétiques
WO2013183712A1 (fr) *	2012-06-06	2013-12-12	日本碍子株式会社	Dispositif de chromatographie et son utilisation
CN106662582B (zh)	2014-03-07	2019-12-10	加利福尼亚大学董事会	用于整合分析物提取、浓缩和检测的装置
JP2017150815A (ja) *	2014-05-29	2017-08-31	株式会社日立製作所	臨床検査キット及び化学物質検出方法
JP6655845B2 (ja) *	2014-12-05	2020-02-26	国立大学法人神戸大学	ｉｎｖｉｖｏステルス性ナノ粒子
JP2016141665A (ja) *	2015-02-04	2016-08-08	オルテックインコーポレイテッド	アフラトキシン鋳型、分子インプリントポリマー、ならびにその作製法および使用法
JP2016164553A (ja) *	2015-02-27	2016-09-08	株式会社リコー	標的検査装置、標的検査キット、標的検査方法、転写媒体、及び標的検査装置の製造方法
JP2016164554A (ja) *	2015-02-27	2016-09-08	株式会社リコー	標的検査装置、標的検査キット、標的検査方法、転写媒体、及び標的検査装置の製造方法
CN108139402B (zh)	2015-09-04	2022-10-18	加利福尼亚大学董事会	用于临床应用的分析物收集、提取、浓缩和检测的方法和装置
IL261734B2 (en) *	2016-03-15	2023-04-01	Mipsalus Aps	A method for detection and means for it
WO2017214315A1 (fr)	2016-06-09	2017-12-14	The Regents Of The University Of California	Concentration de biomarqueurs et amplification de signaux pour utilisation dans des dosages immunologiques à base de papier et plateforme unique pour extraire, concentrer et amplifier de l'adn
US11327075B2 (en)	2016-08-22	2022-05-10	The Regents Of The University Of California	Hydrogel platform for aqueous two-phase concentration of a target to enhance its detection
US11209427B2 (en)	2017-03-27	2021-12-28	The Regents Of The University Of California	Semi-quantitative lateral-flow immunoassay for the detection of CSF leaks
DE102018220631A1 (de) *	2018-11-29	2020-06-04	B. Braun Melsungen Ag	Wässrige Zusammensetzung, insbesondere zur Behandlung von Schleimhaut und/oder Wunden
KR102352617B1 (ko) *	2019-12-26	2022-01-19	프리시젼바이오 주식회사	다중 면역 분석용 검사 스트립 제조 방법 및 이를 이용하여 제조된 검사 스트립
CN115960377B (zh) *	2022-12-19	2023-07-21	北京工商大学	一种特异性荧光指示片及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN85101019A (zh) *	1984-06-12	1987-01-10	田纳西大学研究公司	免疫微脂粒分析-方法及产品
US6461873B1 (en) *	1999-03-18	2002-10-08	Daniel Catania	Caffeine detector
WO2008007359A2 (fr) *	2006-07-09	2008-01-17	Infigo Diagnostics Ltd.	Dispositifs de diagnostic rapide basés sur des polymères à empreintes moléculaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0001877D0 (sv) *	2000-05-22	2000-05-22	Klaus Mosbach	Molecular imprinting
DE10042023C2 (de) *	2000-08-08	2003-04-10	Biognostic Ag	Kapseln, die feste Teilchen signalerzeugender Substanzen einkapseln, und deren Verwendung bei Bioassays zum Nachweis von Zielmolekülen in einer Probe
US20060177882A1 (en) *	2005-02-04	2006-08-10	Samad Talebpour	Immunoassays with enhanced selectivity

2008
- 2008-12-28 WO PCT/IL2008/001688 patent/WO2009083975A2/fr active Application Filing
- 2008-12-28 JP JP2010540221A patent/JP2011508233A/ja active Pending
- 2008-12-28 EP EP08868717A patent/EP2245135A4/fr not_active Withdrawn
- 2008-12-28 CN CN2008801268886A patent/CN101945990A/zh active Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN85101019A (zh) *	1984-06-12	1987-01-10	田纳西大学研究公司	免疫微脂粒分析-方法及产品
US6461873B1 (en) *	1999-03-18	2002-10-08	Daniel Catania	Caffeine detector
WO2008007359A2 (fr) *	2006-07-09	2008-01-17	Infigo Diagnostics Ltd.	Dispositifs de diagnostic rapide basés sur des polymères à empreintes moléculaires

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102507261A (zh) *	2011-10-20	2012-06-20	东北大学	一种选择性定量采集水环境中砷的方法
CN102417558A (zh) *	2011-11-21	2012-04-18	嘉兴学院	一种分离莠去津的磁性分子印记聚合物及其制备方法
CN102417558B (zh) *	2011-11-21	2013-09-04	嘉兴学院	一种分离莠去津的磁性分子印记聚合物及其制备方法
CN105004855A (zh) *	2014-04-16	2015-10-28	万冰	一种侧向流动检测测试条
CN105004855B (zh) *	2014-04-16	2017-05-31	万冰	一种侧向流动检测测试条
CN113731518A (zh) *	2016-03-18	2021-12-03	奎多心血管股份有限公司	微流体装置、系统及方法
CN113731518B (zh) *	2016-03-18	2022-11-25	奎多心血管股份有限公司	微流体装置、系统及方法
CN107478759A (zh) *	2016-06-08	2017-12-15	南京医科大学	基于分子印记纳米磁珠与质谱联用用于大鼠粪便中三七总皂苷代谢物质群的检测方法
CN106526176A (zh) *	2016-12-05	2017-03-22	无锡艾科瑞思产品设计与研究有限公司	一种多功能荧光免疫层析快速定量检测卡
CN106645109A (zh) *	2016-12-29	2017-05-10	Tcl集团股份有限公司	一种检测激素的方法、装置及系统
CN106872689A (zh) *	2017-01-10	2017-06-20	宁波大学	一种快速测定磺胺类抗生素残留的仿生酶联免疫检测方法
CN111116823A (zh) *	2018-10-31	2020-05-08	华中科技大学	一种筛选甲状腺素干扰物材料的制备方法及应用

Also Published As

Publication number	Publication date
WO2009083975A2 (fr)	2009-07-09
EP2245135A2 (fr)	2010-11-03
JP2011508233A (ja)	2011-03-10
EP2245135A4 (fr)	2011-01-12
WO2009083975A3 (fr)	2010-03-11

Publication	Publication Date	Title
CN101945990A (zh)	2011-01-12	基于分子印记聚合物的小分子和蛋白质分析装置
US20130102063A1 (en)	2013-04-25	Small molecules and protein analysis devices based on molecular imprinted polymers
AU748387B2 (en)	2002-06-06	Neutralization of polycations in a chromatographic device for whole blood use
JP3126383B2 (ja)	2001-01-22	簡易な分析装置
US6689317B1 (en)	2004-02-10	Immunoassay apparatus for diagnosis
HK1080142B (zh)	2013-10-11	敏感性免疫色原图像测试
EP2041567A2 (fr)	2009-04-01	Dispositifs de diagnostic rapide bases sur des polymeres a empreintes moleculaires
EP1882184A1 (fr)	2008-01-30	Essai d'immunochromatographie rapide de fluide oral
JP2009506319A (ja)	2009-02-12	多角的イムノクロマトグラフィーアッセイ
JP4545869B2 (ja)	2010-09-15	多孔性フィルタを用いる生理活性試料物質の測定方法
JPS5984162A (ja)	1984-05-15	免疫分析法
CN102066899A (zh)	2011-05-18	建立针对生物来源之起始材料中多种分析物的标准品的方法
US6410251B2 (en)	2002-06-25	Method for detecting or assaying target substance by utilizing oxygen electrode
KR101726181B1 (ko)	2017-04-13	면역크로마토그래피 분석용 디바이스
WO2005069002A1 (fr)	2005-07-28	Test rapide de detection d'anticorps diriges contre le vih dans les urines
JP4653574B2 (ja)	2011-03-16	ヘモグロビンＡ１ｃの測定方法
Aberl et al.	1992	An ISFET-based FIA system for immunosensing
US20190353646A1 (en)	2019-11-21	Device and method to determine or quantify the presence of an analyte molecule
RU2686490C1 (ru)	2019-04-29	Набор для мультиплексного иммунохимического анализа антител и антигенов в препаратах крови
JP3713178B2 (ja)	2005-11-02	梅毒抗体検出用免疫分析装置
EP1406089A1 (fr)	2004-04-07	Une méthode pour marquer des protéines solubles dans l'eau sélectivement avec colorants réactifs
Ferguson	2009	Saliva as a diagnostic fluid
KR20230057939A (ko)	2023-05-02	중력을 이용하는 자성입자 기반 바이오칩 및 이를 이용한 분석물질 검출 방법
JP5065355B2 (ja)	2012-10-31	多孔性フィルタを用いる生理活性試料物質の測定方法
Ansell	2004	Application of MIPs as antibody mimics in immunoassays

Legal Events

Date	Code	Title	Description
2011-01-12	C06	Publication
2011-01-12	PB01	Publication
2011-04-06	C10	Entry into substantive examination
2011-04-06	SE01	Entry into force of request for substantive examination
2013-11-06	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2013-11-06	WD01	Invention patent application deemed withdrawn after publication	Application publication date: 20110112